Download PDF
Semin Hear 2001; 22(4): 377-392
DOI: 10.1055/s-2001-19111
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Evoked Otoacoustic Emissions as Objective Screeners for Ototoxicity

Brenda L. Lonsbury-Martin, Glen K. Martin
  • Department of Otolaryngology-Head and Neck Surgery, University of Colorado Health Sciences Center, Denver, Colorado
Further Information

Publication History

Publication Date:
18 December 2001 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Ototoxicity produces hearing losses that are irreversible. The only certain method of preventing debilitating ototoxicity is to detect it as early as possible in the treatment regimen so that medications can be substituted, doses changed, and/or the mode of administration altered. With increasing survival rates of patients requiring ototoxic medication (e.g., aminoglycosides, cisplatin), early detection of ototoxicity is important for providing effective management options. A protocol including the use of otoacoustic emissions to detect and monitor the impact of ototoxicity will be presented.

KEYWORD

Ototoxicity - aminoglycoside - cisplatin - hearing monitoring

REFERENCES

  • 1 American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy.  ASHA . 1994 (Suppl 12);  36 11-19
    PubMedSearch in Google Scholar
  • 2 Fausti S A, Henry J A, Helt W J. An individualized, sensitive frequency range for early detection of ototoxicity.  Ear Hear . 1999;  20 497-505
    CrossrefPubMedSearch in Google Scholar
  • 3 Wright C G, Schaefer S D. Inner ear histopathology in patients treated with cisplatin.  Laryngoscope . 1982;  92 1408-1413
    PubMedSearch in Google Scholar
  • 4 Myers S F, Blakley B W, Schwan S. Is cis-platinum vestibulotoxic?.  Otolaryngol Head Neck Surg . 1993;  108 322-328
    PubMedSearch in Google Scholar
  • 5 Strauss M, Towfighi J, Lord S, Lipton A, Harvey H A, Brown B. Cis-platinum ototoxicity: Clinical experience and temporal bone histopathology.  Laryngoscope . 1983;  93 1554-1559
    PubMedSearch in Google Scholar
  • 6 Priuska E M, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex.  Biochem Pharmacol . 1995;  50 1749-1752
    CrossrefPubMedSearch in Google Scholar
  • 7 Sha S H, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.  Hear Res . 2001;  155 1-8
    CrossrefPubMedSearch in Google Scholar
  • 8 McAlpine A, Johnstone B M. The ototoxic mechanism of cisplatin.  Hear Res . 1990;  47 191-204
    CrossrefPubMedSearch in Google Scholar
  • 9 Kemp D T. Stimulated acoustic emissions from within the human auditory system.  J Acoust Soc Am . 1978;  64 1386-1391
    CrossrefPubMedSearch in Google Scholar
  • 10 Kemp D T. Evidence of mechanical nonlinearity and frequency selective wave amplification in the cochlea.  Arch Otorhinolaryngol . 1979;  224 37-45
    PubMedSearch in Google Scholar
  • 11 Henley C M. Kanamycin depletes cochlear polyamines in the developing rat.  Otolaryngol Head Neck Surg . 1994;  110 103-109
    PubMedSearch in Google Scholar
  • 12 McPhee J R, Sperling N M, Madell J R, Lucente F E. Early detection of ototoxicity using high frequency distortion product otoacoustic emissions.  Abstr Assoc Res Otolaryngol . 1994;  17 49
    PubMedSearch in Google Scholar
  • 13 Hotz M A, Harris F P, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity.  Laryngoscope . 1994;  14 1130-1134
    PubMedSearch in Google Scholar
  • 14 Ozturan O, Jerger J, Lew H, Lynch G R. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.  Auris Nasus Larynx . 1996;  23 147-151
    PubMedSearch in Google Scholar
  • 15 Zorowka P G, Schmitt H J, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.  Int J Pediatr Otorhinolaryngol . 1993;  25 73-80
    CrossrefPubMedSearch in Google Scholar
  • 16 Whitehead M L, Stagner B B, Lonsbury-Martin B L, Martin G K. Measurement of otoacoustic emissions for hearing assessment.  IEEE Eng Med Biol . 1994;  13 210-226
    PubMedSearch in Google Scholar
  • 17 Henley C M, Rybak L P. Ototoxicity in developing mammals.  Br Res Rev . 1995;  20 68-90
    PubMedSearch in Google Scholar
  • 18 Allen G C, Tiu C, Koike K, Ritchey A K, Kurs-Lasky M, Wax M K. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy.  Otolaryngol Head Neck Surg . 1988;  118 584-588
    PubMedSearch in Google Scholar
  • 19 Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamapoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children.  Int J Pediatr Otorhinolaryngol . 2001;  59 47-57
    CrossrefPubMedSearch in Google Scholar
  • 20 Ress B D, Sridhar K S, Balkany T J, Waxman G M, Stagner B B, Lonsbury-Martin B L. Effects of cis-platinum chemotherapy on otoacoustic emissions: development of an objective screening protocol.  Otolaryngol Head Neck Surg . 1999;  121 693-701
    CrossrefPubMedSearch in Google Scholar
  • 21 Katbamna B, Homnick D N, Marks J H. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions.  Ear Hear . 1999;  20 393-402
    PubMedSearch in Google Scholar
  • 22 Mulheran M, Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects.  Br J Audiol . 1997;  31 5-9
    CrossrefPubMedSearch in Google Scholar
  • 23 Katona G, Revai K, Farkas Z, Czinner A, Pataki L. Distortion-product otoacoustic emission screening in netilmicin-treated newborns.  J Audiol Med . 1198;  7 10-14
    PubMedSearch in Google Scholar
  • 24 Wax T, DiPietro L. Managing Hearing Loss in Later Life. National Information Center on Deafness (NICD) Washington, DC: Gallaudet University; 1991
    Search in Google Scholar
  • 25 Lonsbury-Martin B L, Cutler W M, Martin G K. Evidence for the influence of aging on distortion-product otoacoustic emissions in humans.  J Acoust Soc Am . 1991;  89 1749-1759
    PubMedSearch in Google Scholar
  • 26 Stover L, Norton S J. The effects of aging on otoacoustic emissions.  J Acoust Soc Am . 1993;  94 2670-2681
    PubMedSearch in Google Scholar
  • 27 Owens J J, McCoy M J, Lonsbury-Martin B L, Martin G K. Influence of otitis media on evoked otoacoustic emissions in children.  Semin Hear . 1992;  13 53-66
    PubMedSearch in Google Scholar
  • 28 Margolis R H, Trine M B. Influence of middle-ear disease on otoacoustic emissions. In: Robinette MS, Glattke TJ, eds. Otoacoustic Emissions: Clinical Applications New York: Thieme 1997: 130-150
    Search in Google Scholar
  • 29 Mencher G T, Novotny G, Mencher L, Gulliver M. Ototoxicity and irradiation: additional etiologies of hearing loss in adults.  J Am Acad Audiol . 1995;  6 351-357
    PubMedSearch in Google Scholar
  • 30 Madasu R, Ruckenstein M J, Leake F, Steere E, Robbins K T. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.  Arch Otolaryngol Head Neck Surg . 1997;  123 978-981
    PubMedSearch in Google Scholar
  • 31 Buhrer C, Weinel P, Sauter S, Reiter A, Riehm H. Acute deafness in a 4-year old girl after a single infusion of cis-platinum.  Pediatr Hematol Oncol . 1990;  7 145-148
    PubMedSearch in Google Scholar
  • 32 Decker T N. General recording considerations and clinical instrument options. In: Robinette MS, Glattke TJ, eds. Otoacoustic Emissions: Clinical Applications New York: Thieme 1997: 307-332
    Search in Google Scholar
  • 33 Sutton L A, Lonsbury-Martin B L, Martin G K, Whitehead M L. Sensitivity of distortion-product otoacoustic emissions in humans to tonal over- exposure: time course of recovery and effects of lowering L2 .  Hear Res . 1994;  75 161-174
    CrossrefPubMedSearch in Google Scholar
  • 34 Gorga M P, Stover L, Neely S T, Montoya D. The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements.  J Acoust Soc Am . 1996;  100 968-977
    PubMedSearch in Google Scholar
  • 35 Dorn P A, Piskorski P, Gorga M P, Neely S T, Keefe D H. Predicting audiometric status from distortion product otoacoustic emissions using multivariate analysis.  Ear Hear . 1999;  20 149-163
    PubMedSearch in Google Scholar